At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction. This is the first definitive morbidity and mortality study to assess a potential therapy for cardiac disease in this underserved patient population.
Kids like Ethan are why Aflac has been a corporate ally for the childhood cancer community for 24 years. Through innovative research and helping provide peace of mind to patients and their families, Aflac’s commitment to helping find a cure for pediatric cancer holds strong. Every child deserves a lifetime.
Novo Nordisk has published its integrated 2018 Annual Report detailing the company’s year-end performance. The report highlights the company’s progression towards long-term targets taking an integrated approach that accounts for financial, social and environmental performance.
Four years ago, a disease that rarely made headlines — Ebola — raged in West Africa. There was no vaccine, treatment or cure. Though the initial response was slow, the international community ultimately mobilized resources, developed scientific innovations and promised to make sure a tragedy on the same scale would never happen again.
In 1992, as a young HIV/AIDS researcher in her native Netherlands, Hanneke Schuitemaker, Ph.D., now Vice President, Global Head of Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines & Prevention B.V., was devoted to learning as much as she could about the disease—and saw her role as that of a researcher, rather than someone who closely interacted with people who were living with HIV.
As part of the prestigious Merck Fellowship for Global Health program, IDRI (Infectious Disease Research Institute) is hosting three Fellows in Seattle for three months to assist IDRI scientists in implementing drug metabolism and pharmacokinetic (DMPK) studies, a critical compon
The Pacific Northwest Research Institute (PNRI) is partnering with three Fellows from the Merck Fellowship for Global Health program to create a comprehensive plan to move a promising antifungal agent from the laboratory to clinical practice. The compound, discovered in the labor
To help brighten the darkest moments of patients’ cancer treatment journeys, LLS created the Light The Night campaign. A series of fundraising walks across the country, Light The Night benefits research to find blood cancer cures and improve the quality of life for patients and their families.
Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to healthcare. Novartis remained the industry leader in access-to-medicine management, and its newly launched Access Principles – which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally – have been highlighted as an innovative practice. The Novartis CEO and members of the Executive Committee now also have access objectives as part of their individual objectives.
In the largest, most robust, industry-leading, and internationally-recognized research of corporate social investment, CECP: The CEO Force for Good, in association with The Conference Board, found in their annual Giving in Numbers: 2018 Edition report that leading corporations are intensifying efforts to meet key societal needs around the world.
The Verizon Foundation serves as an incubator for exploring how our technical and human resources can be applied in new ways to the practical concerns...
Diverse teams build better products — period. At GoDaddy, we make apps and services that our worldwide community of entrepreneurs can relate to. Our...
